Progression of clinical markers in prodromal Parkinson’s disease and dementia with Lewy bodies: a multicentre study
Brain · 01.08.2023 · 146 (8) · 3258-3272
DOI: 10.1093/brain/awad072 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Brain, online erschienen am 07.03.2023. Verfasst von Stephen Joza und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Montreal Neurological Institute, Montreal, Quebec H3A 2B4, Canada. Hauptthemen laut MEDLINE: Parkinson Disease, Lewy Body Disease, REM Sleep Behavior Disorder. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: an Edmond J, Michael J. Fox Foundation.
Themen: Demenz
Abstract (Originalsprache)
The neurodegenerative synucleinopathies, including Parkinson’s disease and dementia with Lewy bodies, are characterized by a typically lengthy prodromal period of progressive subclinical motor and non-motor manifestations. Among these, idiopathic REM sleep behaviour disorder is a powerful early predictor of eventual phenoconversion, and therefore represents a critical opportunity to intervene with neuroprotective therapy. To inform the design of randomized trials, it is essential to study the natural progression of clinical markers during the prodromal stages of disease in order to establish optimal clinical end points. In this study, we combined prospective follow-up data from 28 centres of the International REM Sleep Behavior Disorder Study Group representing 12 countries. Polysomnogram-confirmed REM sleep behaviour disorder subjects were assessed for prodromal Parkinson’s disease using the Movement Disorder Society criteria and underwent periodic structured sleep, motor, cognitive, autonomic and olfactory testing. We used linear mixed-effect modelling to estimate annual rates of clinical marker progression stratified by disease subtype, including prodromal Parkinson’s disease and prodromal dementia with Lewy bodies. In addition, we calculated sample size requirements to demonstrate slowing of progression under different anticipated treatment effects. Overall, 1160 subjects were followed over an average of 3.3 ± 2.2 years. Among clinical variables assessed continuously, motor variables tended to progress faster and required the lowest sample sizes, ranging from 151 to 560 per group (at 50% drug efficacy and 2-year follow-up). By contrast, cognitive, olfactory and autonomic variables showed modest progression with higher variability, resulting in high sample sizes. The most efficient design was a time-to-event analysis using combined milestones of motor and cognitive decline, estimating 117 per group at 50% drug efficacy and 2-year trial duration. Finally, while phenoconverters showed overall greater progression than non-converters in motor, olfactory, cognitive and certain autonomic markers, the only robust difference in progression between Parkinson’s disease and dementia with Lewy bodies phenoconverters was in cognitive testing. This large multicentre study demonstrates the evolution of motor and non-motor manifestations in prodromal synucleinopathy. These findings provide optimized clinical end points and sample size estimates to inform future neuroprotective trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Montreal Neurological Institute, Montreal, Quebec H3A 2B4, Canada.
- Nuffield Department of Clinical Neurosciences, Division of Neurology and Oxford Parkinson's Disease Centre, University of Oxford, Oxford OX3 9DU, UK.
- Department of Neurology, Seoul National University College of Medicine, Seoul National University Hospital, 03080 Seoul, Republic of Korea.
- Clinic for Sleep & Chronomedicine, St. Hedwig-Krankenhaus, 10115 Berlin, Germany.
- Medical University Innsbruck, Department of Neurology, 6020 Innsbruck, Austria.
- Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, 116 36 Prague, Czech Republic.
ORCID-Profile: Stephen Joza, Ki-Young Jung, Dieter Kunz, Ambra Stefani, Michele Terzaghi, Dario Arnaldi, Jee-Young Lee, Federica Provini, Yves Dauvilliers, Raffaele Ferri, Annette Janzen, Giuseppe Lanza, Jun-Sang Sunwoo
Förderung
- an Edmond J
- Michael J. Fox Foundation
Zitieren
APA
Joza, S., Hu, M. T., Jung, K. Y., Kunz, D., Stefani, A., Dušek, P., Terzaghi, M., Arnaldi, D., Videnovic, A., Schiess, M. C., Hermann, W., Lee, J. Y., Ferini-Strambi, L., Lewis, S. J. G., Leclair-Visonneau, L., Oertel, W. H., Antelmi, E., Sixel-Döring, F., Cochen De Cock, V., …, & Postuma, R. B. (2023). Progression of clinical markers in prodromal Parkinson’s disease and dementia with Lewy bodies: a multicentre study. Brain, 146(8), 3258-3272. https://doi.org/10.1093/brain/awad072
Vancouver
Joza S, Hu MT, Jung KY, Kunz D, Stefani A, Dušek P, et al. Progression of clinical markers in prodromal Parkinson’s disease and dementia with Lewy bodies: a multicentre study. Brain. 2023;146(8):3258-3272. doi:10.1093/brain/awad072
BibTeX
@article{Joza2023,
author = {Joza, Stephen and Hu, Michele T and Jung, Ki-Young and Kunz, Dieter and Stefani, Ambra and Dušek, Petr and Terzaghi, Michele and Arnaldi, Dario and Videnovic, Aleksandar and Schiess, Mya C and Hermann, Wiebke and Lee, Jee-Young and Ferini-Strambi, Luigi and Lewis, Simon J G and Leclair-Visonneau, Laurène and Oertel, Wolfgang H and Antelmi, Elena and Sixel-Döring, Friederike and Cochen De Cock, Valérie and Liguori, Claudio and Liu, Jun and Provini, Federica and Puligheddu, Monica and Nicoletti, Alessandra and Bassetti, Claudio L A and Bušková, Jitka and Dauvilliers, Yves and Ferri, Raffaele and Montplaisir, Jacques Y and Lawton, Michael and Kim, Han-Joon and Bes, Frederik and Högl, Birgit and Šonka, Karel and Fiamingo, Giuseppe and Mattioli, Pietro and Lavadia, Maria Lorena and Suescun, Jessika and Woo, Kyung Ah and Marelli, Sara and Martens, Kaylena Ehgoetz and Janzen, Annette and Plazzi, Giuseppe and Mollenhauer, Brit and Fernandes, Mariana and Li, Yuanyuan and Cortelli, Pietro and Figorilli, Michela and Cicero, Calogero Edoardo and Schaefer, Carolin and Guiraud, Lily and Lanza, Giuseppe and Gagnon, Jean-François and Sunwoo, Jun-Sang and Ibrahim, Abubaker and Girtler, Nicola and Trenkwalder, Claudia and Baldelli, Luca and Pelletier, Amelie and Postuma, Ronald B},
title = {Progression of clinical markers in prodromal Parkinson’s disease and dementia with Lewy bodies: a multicentre study},
journal = {Brain},
year = {2023},
volume = {146},
number = {8},
pages = {3258--3272},
doi = {10.1093/brain/awad072}
}
EUVIMED